Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Public ClinicalTrials.gov record NCT03997123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.
Study identification
- NCT ID
- NCT03997123
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 923 participants
Conditions and interventions
Conditions
Interventions
- Capivasertib Drug
- Paclitaxel Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2019
- Primary completion
- Mar 15, 2026
- Completion
- Mar 15, 2026
- Last update posted
- Dec 21, 2025
2019 – 2026
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Whittier | California | 90602 | — |
| Research Site | Whittier | California | 90603 | — |
| Research Site | Fort Myers | Florida | 33901 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | St. Petersburg | Florida | 33705 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Westwood | Kansas | 66205 | — |
| Research Site | Silver Spring | Maryland | 20910 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Nyack | New York | 10960 | — |
| Research Site | Cincinnati | Ohio | 45220 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Harrisburg | Pennsylvania | 17109 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Austin | Texas | 78758 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 238 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03997123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03997123 live on ClinicalTrials.gov.